Lucarini Valeria, Melaiu Ombretta, Tempora Patrizia, D'Amico Silvia, Locatelli Franco, Fruci Doriana
Department of Paediatric Haematology/Oncology and of Cell and Gene Therapy, Ospedale Pediatrico Bambino Gesù, IRCCS, 00146 Rome, Italy.
Department of Pediatrics, Sapienza University of Rome, 00161 Rome, Italy.
Cancers (Basel). 2021 Jan 23;13(3):433. doi: 10.3390/cancers13030433.
Tumor-infiltrating CD8 T cells have been shown to play a crucial role in controlling tumor progression. However, the recruitment and activation of these immune cells at the tumor site are strictly dependent on several factors, including the presence of dendritic cells (DCs), the main orchestrators of the antitumor immune responses. Among the various DC subsets, the role of cDC1s has been demonstrated in several preclinical experimental mouse models. In addition, the high density of tumor-infiltrating cDC1s has been associated with improved survival in many cancer patients. The ability of cDC1s to modulate antitumor activity depends on their interaction with other immune populations, such as NK cells. This evidence has led to the development of new strategies aimed at increasing the abundance and activity of cDC1s in tumors, thus providing attractive new avenues to enhance antitumor immunity for both established and novel anticancer immunotherapies. In this review, we provide an overview of the various subsets of DCs, focusing in particular on the role of cDC1s, their ability to interact with other intratumoral immune cells, and their prognostic significance on solid tumors. Finally, we outline key therapeutic strategies that promote the immunogenic functions of DCs in cancer immunotherapy.
肿瘤浸润性CD8 T细胞已被证明在控制肿瘤进展中起关键作用。然而，这些免疫细胞在肿瘤部位的募集和激活严格依赖于多种因素，包括树突状细胞（DCs）的存在，DCs是抗肿瘤免疫反应的主要协调者。在各种DC亚群中，cDC1s的作用已在多个临床前实验小鼠模型中得到证实。此外，肿瘤浸润性cDC1s的高密度与许多癌症患者的生存期改善相关。cDC1s调节抗肿瘤活性的能力取决于它们与其他免疫群体（如NK细胞）的相互作用。这一证据促使人们开发新策略，旨在增加肿瘤中cDC1s的数量和活性，从而为既定的和新型的抗癌免疫疗法提供增强抗肿瘤免疫力的有吸引力的新途径。在这篇综述中，我们概述了DCs的各种亚群，特别关注cDC1s的作用、它们与其他肿瘤内免疫细胞相互作用的能力以及它们对实体瘤的预后意义。最后，我们概述了在癌症免疫治疗中促进DCs免疫原性功能的关键治疗策略。
